Published in Can Urol Assoc J on December 09, 2013
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J (2016) 1.08
Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario. Can Urol Assoc J (2014) 0.93
Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. Can Urol Assoc J (2015) 0.84
Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice. Can Urol Assoc J (2016) 0.76
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. Can Urol Assoc J (2014) 0.75
Optimizing care and outcomes of patients with muscle-invasive bladder cancer. Can Urol Assoc J (2014) 0.75
[Not Available]. Can Urol Assoc J (2014) 0.75
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol (2011) 5.95
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol (2005) 4.57
Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet (2003) 3.51
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol (2005) 2.58
Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol (2012) 1.56
Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol (1999) 1.56
Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol (2010) 1.53
Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer (2010) 1.53
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol (2011) 1.51
Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol (1996) 1.38
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int (2011) 1.31
Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int (2010) 1.31
Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol (2012) 1.25
Update on chemotherapy for advanced bladder cancer. J Urol (2005) 1.15
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol (2002) 1.14
Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology (2010) 1.12
Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol (1991) 1.08
Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach. Cancer (2011) 1.02
Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol (1995) 0.87
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int (2012) 0.85
Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urology (1996) 0.81
Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol (2002) 0.80
Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer. Can J Urol (2006) 0.78
Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens. Semin Oncol (1991) 0.77
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol (2013) 2.90
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis (2013) 2.71
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.85
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 1.74
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol (2011) 1.49
New directions for biologic targets in urothelial carcinoma. Mol Cancer Ther (2012) 1.49
Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int (2009) 1.46
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol (2007) 1.42
Laparoscopic partial nephrectomy with "on-demand" clamping reduces warm ischemia time. Eur Urol (2007) 1.40
Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther (2010) 1.39
A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int (2007) 1.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Dosage of enoxaparin among obese and renal impairment patients. Thromb Res (2004) 1.22
Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncol Pract (2013) 1.21
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol (2008) 1.18
A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J (2009) 1.17
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int (2010) 1.15
Insulin-insulin-like growth factor axis and colon cancer. J Clin Oncol (2008) 1.12
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res (2011) 1.11
Repeat prostate biopsy: who, how and when?. a review. Eur Urol (2002) 1.09
Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. World J Urol (2003) 1.08
The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol (2009) 1.08
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs (2007) 1.08
Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol (2013) 1.06
Prostate cancer prevention: past, present, and future. Cancer (2007) 1.05
Contemporary management of postchemotherapy testis cancer. Eur Urol (2012) 1.05
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J (2013) 1.04
A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens. Can Urol Assoc J (2012) 1.03
The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol (2011) 1.03
Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology (2006) 1.03
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther (2013) 1.02
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J (2013) 1.02
Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol (2007) 1.01
Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments. Lab Chip (2013) 1.00
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol (2012) 1.00
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs (2006) 0.99
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer (2004) 0.99
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol (2007) 0.99
Associations between exercise and quality of life in bladder cancer survivors: a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 0.98
Canadian guideline on genetic screening for hereditary renal cell cancers. Can Urol Assoc J (2013) 0.98
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int (2011) 0.98
Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. Front Genet (2012) 0.96
A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J (2009) 0.96
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res (2008) 0.96
Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS One (2013) 0.96
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs (2011) 0.95
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther (2008) 0.94
Prostate cancer: a serious disease suitable for prevention. BJU Int (2009) 0.92
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol (2012) 0.92
Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J (2010) 0.92
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol (2006) 0.92
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int (2012) 0.91
Malignant spinal cord compression secondary to testicular seminoma at the time of initial presentation and at relapse while on surveillance. Can Urol Assoc J (2007) 0.90
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Eur Urol (2012) 0.90
Exercise programming and counseling preferences in bladder cancer survivors: a population-based study. J Cancer Surviv (2007) 0.90
Associations between physical activity and quality of life in a population-based sample of kidney cancer survivors. Cancer Epidemiol Biomarkers Prev (2011) 0.89
Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther (2011) 0.89
To biopsy or not to biopsy--thou shall think twice. Eur Urol (2012) 0.89
Demographic analysis of randomized controlled trials in bladder cancer. BJU Int (2012) 0.89
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics (2012) 0.88
Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PLoS One (2013) 0.87
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol (2007) 0.87
Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J (2008) 0.87
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int (2014) 0.86
Hand-assisted laparoscopic right-donor nephrectomy in a patient with situs inversus. Transplantation (2003) 0.86
Reliability, validity and ease of use of a portable point-of-care coagulation device in a pharmacist-managed anticoagulation clinic. J Thromb Thrombolysis (2002) 0.86
Hereditary renal cell carcinoma associated with von Hippel-Lindau disease: a description of a Nova Scotia cohort. Can Urol Assoc J (2009) 0.86
Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol (2010) 0.85
Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behavior. Int J Behav Nutr Phys Act (2012) 0.85
A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. Support Care Cancer (2008) 0.85